Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 2
2015 1
2016 4
2017 3
2018 1
2019 4
2021 2
2022 3
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson's Disease.
Jennings D, Huntwork-Rodriguez S, Vissers MFJM, Daryani VM, Diaz D, Goo MS, Chen JJ, Maciuca R, Fraser K, Mabrouk OS, van de Wetering de Rooij J, Heuberger JAAC, Groeneveld GJ, Borin MT, Cruz-Herranz A, Graham D, Scearce-Levie K, De Vicente J, Henry AG, Chin P, Ho C, Troyer MD. Jennings D, et al. Among authors: fraser k. Mov Disord. 2023 Mar;38(3):386-398. doi: 10.1002/mds.29297. Epub 2023 Feb 18. Mov Disord. 2023. PMID: 36807624 Clinical Trial.
Trial of Cinpanemab in Early Parkinson's Disease.
Lang AE, Siderowf AD, Macklin EA, Poewe W, Brooks DJ, Fernandez HH, Rascol O, Giladi N, Stocchi F, Tanner CM, Postuma RB, Simon DK, Tolosa E, Mollenhauer B, Cedarbaum JM, Fraser K, Xiao J, Evans KC, Graham DL, Sapir I, Inra J, Hutchison RM, Yang M, Fox T, Budd Haeberlein S, Dam T; SPARK Investigators. Lang AE, et al. Among authors: fraser k. N Engl J Med. 2022 Aug 4;387(5):408-420. doi: 10.1056/NEJMoa2203395. N Engl J Med. 2022. PMID: 35921450 Clinical Trial.
Multiplexed Profiling of Single Extracellular Vesicles.
Lee K, Fraser K, Ghaddar B, Yang K, Kim E, Balaj L, Chiocca EA, Breakefield XO, Lee H, Weissleder R. Lee K, et al. Among authors: fraser k. ACS Nano. 2018 Jan 23;12(1):494-503. doi: 10.1021/acsnano.7b07060. Epub 2018 Jan 4. ACS Nano. 2018. PMID: 29286635 Free PMC article.
Cinpanemab in Early Parkinson Disease: Evaluation of Biomarker Results From the Phase 2 SPARK Clinical Trial.
Hutchison RM, Fraser K, Yang M, Fox T, Hirschhorn E, Njingti E, Scott D, Bedell BJ, Kistner KM, Cedarbaum JM, Evans KC, Graham D, Martarello L, Mollenhauer B, Lang AE, Dam T, Beaver J. Hutchison RM, et al. Among authors: fraser k. Neurology. 2024 Mar 12;102(5):e209137. doi: 10.1212/WNL.0000000000209137. Epub 2024 Feb 5. Neurology. 2024. PMID: 38315945 Clinical Trial.
Glucocerebrosidase Activity is not Associated with Parkinson's Disease Risk or Severity.
Omer N, Giladi N, Gurevich T, Bar-Shira A, Gana-Weisz M, Glinka T, Goldstein O, Kestenbaum M, Cedarbaum JM, Mabrouk OS, Fraser KB, Shirvan JC, Orr-Urtreger A, Mirelman A, Thaler A. Omer N, et al. Among authors: fraser kb. Mov Disord. 2022 Jan;37(1):190-195. doi: 10.1002/mds.28792. Epub 2021 Sep 22. Mov Disord. 2022. PMID: 34550621 Free PMC article.
Glucocerebrosidase Activity Is Not Associated with Parkinson's Disease Risk or Severity.
Omer N, Giladi N, Gurevich T, Bar-Shira A, Gana-Weisz M, Glinka T, Goldstein O, Kestenbaum M, Cedarbaum JM, Mabrouk OS, Fraser KB, Shirvan JC, Orr-Urtreger A, Mirelman A, Thaler A. Omer N, et al. Among authors: fraser kb. Mov Disord. 2022 Mar;37(3):651-652. doi: 10.1002/mds.28929. Epub 2022 Jan 22. Mov Disord. 2022. PMID: 35064687 No abstract available.
25 results